H. B. El-serag, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, vol.142, pp.1264-1273, 2012.

C. Trépo, H. L. Chan, and A. Lok, Hepatitis B virus infection, Lancet, vol.384, pp.2053-2063, 2014.

C. Seeger and S. W. Mason, Molecular biology of hepatitis B virus infection, Virology, vol.33, pp.395-401, 2015.

A. Schulze, P. Gripon, and S. Urban, Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans, Hepatology, vol.46, pp.1759-1768, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00690474

E. R. Verrier, A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses, Hepatology, vol.63, pp.35-48, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01796197

C. Sureau and J. Salisse, A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant, Hepatology, vol.57, pp.985-994, 2013.

H. Yan, Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus, Elife, vol.1, p.49, 2012.

W. Li and S. Urban, Entry of hepatitis B and hepatitis D virus into hepatocytes: basic insights and clinical implications, J. Hepatol, vol.64, pp.32-40, 2016.

C. Königer, Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses, Proc. Natl Acad. Sci. USA, vol.111, pp.4244-4253, 2014.

Y. Qi, DNA polymerase K is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus, PLoS Pathog, vol.12, pp.1-26, 2016.

M. Nassal, HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B, Gut, vol.64, pp.1972-1984, 2015.

T. F. Baumert, E. R. Verrier, M. Nassal, R. T. Chung, and M. B. Zeisel, Hosttargeting agents for treatment of hepatitis B virus infection, Curr. Opin. Virol, vol.14, pp.41-46, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02444512

E. Crouchet, F. Wrensch, C. Schuster, M. B. Zeisel, and T. F. Baumert, Hosttargeting therapies for hepatitis C virus infection: current developments and future applications, Ther. Adv. Gastroenterol, vol.11, pp.1-15, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02460232

Y. Xia and T. J. Liang, Development of direct-acting antiviral and host-targeting agents for treatment of hepatitis B virus infection, Gastroenterology, vol.156, pp.311-324, 2019.

E. Bekerman and S. Einav, Combating emerging viral threats, Science, vol.348, pp.282-283, 2015.

Y. Ni, Hepatitis B and D viruses exploit sodium taurocholate cotransporting polypeptide for species-specific entry into hepatocytes, Gastroenterology, vol.146, pp.1070-1083, 2014.

F. A. Lempp, B. Qu, Y. Wang, S. Urban, and B. Hepatitis, Virus Infection of a mouse hepatic cell line reconstituted with human sodium taurocholate cotransporting, J. Virol, vol.90, pp.4827-4831, 2016.

X. Yang, A public genome-scale lentiviral expression library of human ORFs, Nat. Methods, vol.8, pp.659-661, 2011.

A. K. Raney, J. L. Johnson, C. N. Palmer, and A. Mclachlan, Members of the nuclear receptor superfamily regulate transcription from the hepatitis B virus nucleocapsid promoter, J. Virol, vol.71, pp.1058-1071, 1997.

H. Ishida, Identification of multiple transcription factors, HLF, FTF, and E4BP4, controlling hepatitis B virus enhancer II, J. Virol, vol.74, pp.1241-1251, 2000.

B. Israelow, C. M. Narbus, M. Sourisseau, and M. J. Evans, HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection, Hepatology, vol.60, pp.1170-1179, 2014.

P. B. Devhare, S. Desai, and K. S. Lole, Innate immune responses in human hepatocyte-derived cell lines alter genotype 1 hepatitis E virus replication efficiencies, Sci. Rep, vol.6, p.26827, 2016.

X. Song, Cloning and characterization of a novel spermiogenesisrelated gene, T6441, in rat testis, Front. Biosci, vol.11, pp.143-150, 2006.

A. König, Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells, J. Hepatol, vol.71, pp.289-300, 2019.

D. W. Fry, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts, Mol. Cancer Ther, vol.3, pp.1427-1438, 2004.

S. Kim, LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6 -reactivating Rb in cancer, Mol. Cancer Ther, vol.12, p.2, 2013.

W. Guo, M. Chen, and T. S. Yen, Hepatocyte-specific expression of the hepatitis B virus core promoter depends on both positive and negative regulation, Mol. Cell. Biol, vol.13, pp.443-448, 1993.

D. H. Kim, H. S. Kang, and K. Kim, Roles of hepatocyte nuclear factors in hepatitis B virus infection, World J. Gastroenterol, vol.22, pp.7017-7029, 2016.

H. Tang and A. Mclachlan, Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism, Proc. Natl Acad. Sci. USA, vol.98, pp.1841-1846, 2001.

T. W. Bebee, The splicing regulators Esrp1 and Esrp2 direct an epithelial splicing program essential for mammalian development, Elife, vol.4, p.8954, 2015.

D. Candotti and J. Allain, Biological and clinical significance of hepatitis B virus RNA splicing: an update, Ann. Blood, vol.2, pp.1-14, 2017.

D. P. Aden, A. Fogel, S. Plotkin, I. Damjanov, and B. B. Knowles, Controlled synthesis of HBsAg in a differentited human liver carcinoma-derived cell line, Nature, vol.282, pp.615-616, 1979.

C. Sureau, J. Romet-lemonne, J. I. Mullins, and M. Essex, Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA, Cell, vol.47, pp.37-47, 1986.

A. Ozer, Effect of hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication, Gastroenterology, vol.110, pp.1519-1528, 1996.

A. Schulze, K. Mills, T. S. Weiss, and S. Urban, Hepatocyte polarization is essential for the productive entry of the hepatitis B virus, Hepatology, vol.55, pp.373-383, 2012.

L. De-abreu-costa, Dimethyl sulfoxide (DMSO) decreases cell proliferation and TNF-?, IFN-?, and IL-2 cytokines production in cultures of peripheral blood lymphocytes, Molecules, vol.22, p.1789, 2017.

T. Wang, Hepatitis B virus induces G1 phase arrest by regulating cell cycle genes in HepG2.2.15 cells, Virol. J, vol.8, pp.1-8, 2011.

Y. Xia, Hepatitis B virus deregulates cell cycle to promote viral replication and a premalignant phenotype, J. Virol, vol.92, pp.722-740, 2018.

K. Vermeulen, D. R. Van-bockstaele, and Z. N. Berneman, The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer, Cell Prolif, vol.36, pp.131-149, 2003.

L. Ludgate, Cyclin-dependent kinase 2 phosphorylates S/T-P sites in the hepadnavirus core protein C-terminal domain and is incorporated into viral capsids, J. Virol, vol.86, pp.12237-12250, 2012.

J. Hu, Cyclin E2-CDK2 mediates SAMHD1 phosphorylation to abrogate its restriction of HBV replication in hepatoma cells, FEBS Lett, vol.592, pp.1893-1904, 2018.

M. Yamamoto, CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses, J. Clin. Invest, vol.124, pp.3479-3488, 2014.

T. Tanaka, Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation, Antivir. Res, vol.133, pp.156-164, 2016.

D. L. Burkhart and J. Sage, Cellular mechanisms of tumour suppression by the retinoblastoma gene, Nat. Rev. Cancer, vol.8, pp.671-682, 2008.

K. Guan, Growth suppression by p18, a p16-and p14-related CDK6 inhibitor, correlates with wild-type pRb function, Genes Dev, vol.8, pp.2939-2952, 1994.

Y. Sato, Regulatory signatures of liver regeneration distilled by integrative analysis of mRNA, histone methylation, and proteomics, J. Biol. Chem, vol.292, pp.8019-8037, 2017.

F. P. Reiter, Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells, Cell. Oncol, vol.42, pp.705-715, 2019.

B. Halgand, Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: a nosological and prognostic determinant, Hepatology, vol.67, pp.86-96, 2018.

H. I. Kawsar, Reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis, Clin. Adv. Hematol. Oncol, vol.10, pp.370-378, 2012.

R. M. Galbraith, A. L. Eddleston, R. Williams, A. J. Zuckerman, and K. D. Bagshawe, Fulminant hepatic failure in leukaemia and choriocarinoma related to withdrawal of cytotoxic drug therapy, Lancet, vol.2, pp.528-530, 1975.

S. Vijayaraghavan and S. Moulder, Inhibiting CDK in cancer therapy: current evidence and future directions, Target. Oncol, vol.13, pp.21-38, 2018.

G. E. Konecny, Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer, Clin. Cancer Res, vol.17, pp.1591-1602, 2011.

L. Cen, p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells, Neuro Oncol, vol.14, p.881, 2012.

J. E. Logan, PD-0332991, a potent and selective inhibitor of cyclindependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity, Anticancer Res, vol.33, pp.2997-3004, 2013.

S. J. Littman, C. Brus, and A. Burkart, A phase II study of palbociclib (PD-0332991) in adult patients with advanced hepatocellular carcinoma, J. Clin. Oncol, vol.33, pp.277-277, 2015.

J. Bollard, PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma, Gut, vol.66, pp.1286-1296, 2017.

E. R. Verrier, Solute carrier NTCP regulates innate antiviral immune responses targeting hepatitis C virus infection of hepatocytes, Cell Rep, vol.17, pp.1357-1368, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01911211

J. Lupberger, EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy, Nat. Med, vol.17, pp.589-595, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00705829

S. K. Ladner, Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication, Antimicrob. Agents Chemother, vol.41, pp.1715-1720, 1997.

E. R. Verrier, Hepatitis B virus evasion from cyclic guanosine monophosphate-adenosine monophosphate synthase sensing in human hepatocytes, Hepatology, vol.68, pp.1695-1709, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01981524

E. R. Verrier, Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets, Gut, vol.69, pp.158-167, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02316951

J. Lucifora, Detection of the hepatitis B virus (HBV) covalently-closedcircular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector, Antivir. Res, vol.145, pp.14-19, 2017.

W. Gao and J. Hu, Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein, J. Virol, vol.81, pp.6164-6174, 2007.

F. Habersetzer, Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection, Liver Int, vol.35, pp.130-139, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01488141

S. A. Hughes, H. Wedemeyer, and P. M. Harrison, Hepatitis delta virus, Lancet, vol.378, pp.73-85, 2011.

J. G. Doench, Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9, Nat. Biotechnol, vol.34, pp.1-12, 2016.

F. Piccioni, S. T. Younger, and D. E. Root, Pooled lentiviral-delivery genetic screens, Curr. Protoc. Mol. Biol, vol.121, 2018.

M. Uhlén, Proteomics. Tissue-based map of the human proteome, Science, vol.347, p.1260419, 2015.

A. Subramanian, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide, Proc. Natl Acad. Sci. USA, vol.102, pp.15545-15550, 2005.

W. Zhou, Predictive model for inflammation grades of chronic hepatitis B: scale analysis of clinical parameters and gene expressions, Liver Int, vol.37, pp.1632-1641, 2017.

S. Nakagawa, Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition, Cancer Cell, vol.30, pp.879-890, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02312659

M. Wang, Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis, Sci. Rep, vol.7, p.43446, 2017.

H. Dong, Identification of HBV-MLL4 integration and its molecular basis in Chinese hepatocellular carcinoma, PLoS ONE, vol.10, p.123175, 2015.

S. Roessler, A unique metastasis gene signature enables prediction of tumor relapse in early stage hepatocellular carcinoma patients, Cancer Res, vol.70, pp.10202-10212, 2010.

B. J. Erickson, Radiology data from The Cancer Genome Atlas Liver Hepatocellular Carcinoma [TCGA-LIHC] collection. The Cancer Imaging Archive, 2016.

. Research, -338606-245517) and the Canadian Network on Hepatitis C. E.R.V. acknowledges fellowship from ANRS (ECTZ50121), 201411.